Early development of metabolic syndrome in patients subjected to lung transplantation

Clinical Transplantation

Volumn 27, Issue 3, 2013, Pages

  Savioli, Gabriele ^a   Surbone, Sara ^a   Giovi, Ilaria ^a   Salinaro, Francesco ^a   Preti, Paola ^a   Meloni, Federica ^a   Oggionni, Tiberio ^a   Perlini, Stefano ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Cardiovascular risk; Diabetes; Dyslipidemia; Hypertension; Immunosuppressive therapy; Metabolic syndrome; Solid organ transplantation

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; COHORT ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DYSLIPIDEMIA; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HUMAN; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NEPHROTOXICITY; PREVALENCE; PRIORITY JOURNAL; RISK MANAGEMENT; CARDIOVASCULAR DISEASES; COMPLICATION; DYSLIPIDEMIAS; ITALY; LUNG DISEASES; MIDDLE AGED; POSTOPERATIVE COMPLICATION; PROGNOSIS; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETES MELLITUS; DYSLIPIDEMIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; ITALY; LUNG DISEASES; LUNG TRANSPLANTATION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PREVALENCE; PROGNOSIS; RISK FACTORS;

EID: 84878623468     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12098     Document Type: Article

References (51)

1. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001: 72(6 Suppl): S5.
2. Gallo P, Agozzino L, Angelini A et al. Causes of late failure after heart transplantation: a ten-year survey. J Heart Lung Transplant 1997: 16: 1113.
3. Asfar S, Metrakos P, Fryer J et al. An analysis of late deaths after liver transplantation. Transplantation 1996: 61: 1377.
4. Christie JD, Edwards LB, Kucheryavaya AY et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth Adult Lung and Heart-Lung Transplant Report-2011. J Heart Lung Transplant 2011: 30: 1104.
5. Guckelberger O, Bechstein WO, Neuhaus R et al. Cardiovascular risk factors in long-term follow-up after orthotopic liver transplantation. Clin Transplant 1997: 11: 60.
6. Rice M, Martin J, Hathaway D, Tolley E. Prevalence of cardiovascular risk factors before kidney transplantation. Prog Transplant 2002: 12: 299.
7. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002: 2: 807.
8. Pham PT, Pham PM, Pham SV, Pham PA, Pham PC. New onset diabetes after transplantation (NODAT): an overview. Diabetes Metab Syndr Obes 2011: 4: 175.
9. Silverborn M, Jeppsson A, Martensson G, Nilsson F. New-onset cardiovascular risk factors in lung transplant recipients. J Heart Lung Transplant 2005: 24: 1536.
10. Rakel A, Karelis AD. New-onset diabetes after transplantation: risk factors and clinical impact. Diabetes Metab 2011: 37: 1.
11. Zidek W, Naditch-Brule L, Perlini S, Farsang C, Kjeldsen SE. Blood pressure control and components of the metabolic syndrome: the GOOD survey. Cardiovasc Diabetol 2009: 8: 51.
12. Farsang C, Naditch-Brule L, Perlini S, Zidek W, Kjeldsen SE, GOOD Investigators. Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey. J Hum Hypertens 2009: 23: 316.
13. Kjeldsen SE, Naditch-Brule L, Perlini S, Zidek W, Farsang C. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. J Hypertens 2008: 26: 2064.
14. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001: 24: 683.
15. MacDonald TM, Morant SV, Mozaffari E. Treatment patterns of hypertension and dyslipidaemia in hypertensive patients at higher and lower risk of cardiovascular disease in primary care in the United Kingdom. J Hum Hypertens 2007: 21: 925.
16. Resnick HE, Bergman RN, Henderson JA, Nez-Henderson P, Howard BV. Utility of a surrogate measure of insulin resistance in American Indians: the Strong Heart Study. Ethn Dis 2002: 12: 523.
17. Schillaci G, Pirro M, Vaudo G et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004: 43: 1817.
18. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, American Heart Association; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109: 433.
19. Egan BM, Papademetriou V, Wofford M et al. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertens 2005: 18: 3.
20. Hanefeld M, Koehler C, Gallo S, Benke I, Ott P. Impact of the individual components of the metabolic syndrome and their different combinations on the prevalence of atherosclerotic vascular disease in type 2 diabetes: the Diabetes in Germany (DIG) study. Cardiovasc Diabetol 2007: 6: 13.
21. Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009: 120: 1640.
22. Mancia G, De Backer G, Dominiczak A et al. 2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens 2007: 25: 1751.
23. Reiner Z, Catapano AL, de Backer G et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011: 32: 1769.
24. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988: 37: 1595.
25. Wilson PW, D'Agostino RB, Parise H, Sullivan L, Meigs JB. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation 2005: 112: 3066.
26. Ho JS, Cannaday JJ, Barlow CE, Mitchell TL, Cooper KH, FitzGerald SJ. Relation of the number of metabolic syndrome risk factors with all-cause and cardiovascular mortality. Am J Cardiol 2008: 102: 689.
27. Gami AS, Witt BJ, Howard DE et al. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007: 49: 403.
28. Falcao-Pires I, Palladini G, Goncalves N et al. Distinct mechanisms for diastolic dysfunction in diabetes mellitus and chronic pressure-overload. Basic Res Cardiol 2011: 106: 801.
29. Perlini S, Naditch-Brule L, Farsang C, Zidek W, Kjeldsen SE. Pulse pressure and heart rate in patients with metabolic syndrome across Europe: insights from the GOOD survey. J Hum Hypertens 2012: Dec 13. doi: 10.1038/jhh.2012.61. [Epub ahead of print].
30. Fox CS, Massaro JM, Hoffmann U et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 2007: 116: 39.
31. Smith SR, Lovejoy JC, Greenway F et al. Contributions of total body fat, abdominal subcutaneous adipose tissue compartments, and visceral adipose tissue to the metabolic complications of obesity. Metabolism 2001: 50: 425.
32. Sharif A, Baboolal K. Metabolic syndrome and solid-organ transplantation. Am J Transplant 2010: 10: 12.
33. Hjelmesaeth J, Flyvbjerg A, Jenssen T et al. Hypoadiponectinemia is associated with insulin resistance and glucose intolerance after renal transplantation: impact of immunosuppressive and antihypertensive drug therapy. Clin J Am Soc Nephrol 2006: 1: 575.
34. Watt KD, Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010: 53: 199.
35. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010: CD007893.
36. Taler SJ, Textor SC, Canzanello VJ, Schwartz L. Cyclosporin-induced hypertension: incidence, pathogenesis and management. Drug Saf 1999: 20: 437.
37. Subramanian S, Trence DL. Immunosuppressive agents: effects on glucose and lipid metabolism. Endocrinol Metab Clin North Am 2007: 36: 891.
38. Vallin M, Guillaud O, Morard I et al. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. Clin Transplant 2011: 25: 660.
39. Porrini E, Delgado P, Bigo C et al. Impact of metabolic syndrome on graft function and survival after cadaveric renal transplantation. Am J Kidney Dis 2006: 48: 134.
40. De Vries AP, Bakker SJ, van Son WJ et al. Metabolic syndrome is associated with impaired long-term renal allograft function; not all component criteria contribute equally. Am J Transplant 2004: 4: 1675.
41. Courivaud C, Kazory A, Simula-Faivre D, Chalopin JM, Ducloux D. Metabolic syndrome and atherosclerotic events in renal transplant recipients. Transplantation 2007: 83: 1577.
42. Hanouneh IA, Feldstein AE, McCullough AJ et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008: 14: 1287.
43. Laryea M, Watt KD, Molinari M et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007: 13: 1109.
44. Sanchez-Gomez JM, Martinez-Dolz L, Sanchez-Lazaro I et al. Influence of metabolic syndrome on development of cardiac allograft vasculopathy in the transplanted heart. Transplantation 2012: 93: 106.
45. Paris C, Yates L, Lama P, Zepeda AJ, Gutierrez D, Palma J. Evaluation of metabolic syndrome after hematopoietic stem cell transplantation in children and adolescents. Pediatr Blood Cancer 2012: 59: 306.
46. Airaghi L, Usardi P, Forti S et al. A comparison between metabolic syndrome post-hematopoietic stem cell transplantation and spontaneously occurring metabolic syndrome. J Endocrinol Invest 2011: 34: e6.
47. Israni AK, Snyder JJ, Skeans MA, Kasiske BL, Port Investigators Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant. Transpl Int 2012: 25: 748.
48. Raichlin ER, McConnell JP, Lerman A et al. Systemic inflammation and metabolic syndrome in cardiac allograft vasculopathy. J Heart Lung Transplant 2007: 26: 826.
49. Heuer M, Kaiser GM, Kahraman A et al. Liver transplantation in nonalcoholic steatohepatitis is associated with high mortality and post-transplant complications: a single-center experience. Digestion 2012: 86: 107.
50. Forli L, Bollerslev J, Simonsen S et al. Disturbed energy metabolism after lung and heart transplantation. Clin Transplant 2011: 25: E136.
51. Mokdad AH, Ford ES, Bowman BA et al. Diabetes trends in the U.S.: 1990-1998. Diabetes Care 2000: 23: 1278.